TrialCancer immunology, immunotherapy : CII2010

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

Rodolfo Passalacqua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.